I suspect that continuing advances in treatment will see increased involvement of the private sector - and why not?
On the other hand, one could ask 'Why?'
I was looking at a story in the financial Times this morning, albeit written from a different angle.
This is the start of it:
Immunocore is a success story for the UK’s ambitions in biotechnology. Spun out of Oxford university in 1999, it is pioneering a new generation of medicines to treat cancers, viral infections and autoimmune diseases from the leafy market town of Abingdon-on-Thames.
But for Sir John Bell, the Canadian-British chair of the company and one of the world’s leading immunologists, its story stands out for a less distinguished reason. “Immunocore is, I fear, a classic example of what the UK has been losing,” he says.
The story is about the company's failure to attract UK private investment, but it links in my mind to the book I've recently reading by economist Maria Mazzucato. Her book is about the large investment successive US governments have made in supporting R & D in various fields, and in start ups seeking to use the resultant new technologies. The US governments take the risks because private investors are unwilling to.
I don't exactly know what 'advances in treatment' GSM is referring to, but it seems to me that some may very well emanate from our universities, as did the work Immunocore is developing. It strikes me that if a pioneering UK company cannot get private investment in the UK why isn't our government investing? Why is it being left to find overseas investment with the potential for much of its profits to leave the UK. Additionally, new treatments resulting from state investment could be used in the NHS at a lower cost than via a private company.
It's not as though the NHS has never implemented new treatments and technologies in the past. It's mainly the obsession with the 'in efficiency ' of the market that has led to increased use of private services.